Furthermore, REGN5093-M114 demonstrated potency in reducing tumor growth in EGFR-mutant NSCLC cases with specific genetic alterations, such as PTEN loss or MET Y1230C mutation, especially after previous treatment with osimertinib and savolitinib. This evidence concerns the gene MET and non-small cell lung carcinoma.